Progression-free survival was at least 9.6 months in Stage III subjects (median not reached), and 3.1 months in Stage IV subjects

Overall survival was a secondary endpoint in the study, which previously met its progression-free survival primary endpoint

Anti-neuroblastoma activity was evident by a 50 percent progression-free survival rate at 12 months and included one complete remission based on a normalized MIBG scan and three patients with improved MIBG scan and normalized bone marrow histology over prolonged follow-up (up to 37+months

Pfizer Inc., of New York, said its ALK inhibitor Xalkori (crizotinib) met its primary endpoint in the PROFILE 1007 study, demonstrating significantly improved progression-free survival (PFS) when compared with pemetrexed or docetaxel, in previously treated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC

The primary endpoint of the trial is overall survival, with secondary endpoints of disease-free survival, safety, toxicity and immunological responses

Median progression-free survival was 14 weeks both in patients with and without prior mTOR inhibitor therapy...Progression-free survival with a median follow-up of 17.5 months is 87.7 percent in the relapsed/refractory 420 mg cohort and high-risk relapsed/refractory patients with 17 p deletion and IgVH unmutated status have an estimated 18-month PFS of greater than 70 percent and 80 percent, respectively

Bristol-Myers Squibb Co., of New York, reported six-year follow-up results from a Phase III trial of Sprycel (dasatinib) in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia adult patients resistant or intolerant to Glivec (imatinib, Novartis AG), demonstrating a progression-free survival rate of 49.3 percent and an overall survival rate of 71 percent for patients receiving dasatinib, with 6 percent of patients progressing to accelerated or blast phase of the study at six

The double-blind, placebo-controlled study, being conducted under an FDA special protocol assessment, is designed to enroll more than 1,000 patients with resected Stage IIb, IIc or III melanoma in Europe and the U.S. The biotech expects to reach the recurrence-free survival endpoint by mid-2016 and file an early biologic license application...Progression-free survival is the primary endpoint for accelerated approval, with overall survival as the primary endpoint for full approval in the

The primary endpoint is progression-free survival

Secondary endpoints include progression-free survival and safety

The primary endpoint is progression-free survival

NewLink Genetics Corp., of Ames, Iowa, said data from the 69-patient Phase II trial testing HyperAcute Pancreas immunotherapy, also known as Algenpantucel-L, showed 12-month disease-free survival (DFS) of 62 percent, the primary endpoint of the study

Pfizer Inc., of New York, said the Phase III INTORSECT study testing Torisel (temsirolimus) in patients with advanced renal cell carcinoma whose disease had progressed on or after Sutent (sunitinib malate) therapy did not meet the primary endpoint of prolonging progression-free survival (PFS) when compared to Nexavar (sorafenib, Onyx Pharmaceuticals Inc. and Bayer AG

The primary endpoint is overall survival, and secondary endpoints include overall response, progression-free survival and safety

Secondary endpoints include complete response, progression-free survival and burden of symptoms

The primary endpoint is an estimation of progression-free survival, while secondary endpoints include objective response rate and clinical benefit rate of imetelstat when added to paclitaxel...Idera Pharmaceuticals Inc., of Cambridge, Mass., said top-line results from a Phase II trial of IMO-2055, a Toll-like 9 receptor-targeting candidate, in combination with Erbitux (cetuximab, Eli Lilly and Co.) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who previously

The secondary endpoint of progression-free survival in the ITT population was 5.6 months for the combination arm vs. 4.7 months for the gefitinib-only arm

The trial will assess objective tumor response, with secondary endpoints of complete and partial response, stable disease at four months and progression-free survival

The randomized, double-blind, placebo-controlled trial will evaluate safety and efficacy of single-agent MORAb-004 with supportive care for progression-free survival in patients with chemo-refractory metastatic colorectal cancer